Search Results for keywords:"hearing requests"

The Securities and Exchange Commission (SEC) has published a notice about an application from Antares Private Credit Fund and Antares Capital Credit Advisers LLC. They are seeking an exemption under the Investment Company Act of 1940 to allow certain investment companies to issue multiple classes of shares with different sales fees and service charges. The application was initially filed in May 2024 and amended in November 2024. The SEC will grant the requested relief unless a hearing is ordered, with hearing requests due by December 23, 2024.

Meridian Medical Technologies, LLC has applied to the Drug Enforcement Administration (DEA) to become an importer of certain controlled substances. The company plans to import these substances solely for analytical purposes and has no authorization for other activities involving these drugs. The DEA is accepting public comments or objections to this application until April 14, 2025, and has outlined procedures for submitting these electronically via regulations.gov. Requests for a hearing regarding the application must also be submitted by the same date to designated DEA offices in Springfield, Virginia.

Groff NA Hemplex LLC has applied to the Drug Enforcement Administration to become a registered importer of certain controlled substances. These substances will be imported in bulk to produce research-grade materials for clinical trial studies, specifically involving Marihuana Extract compounds. The application process allows for public comments or objections and requests for a hearing until January 13, 2025. The comments should be submitted electronically through the Federal eRulemaking Portal, while hearing requests must be directed to the DEA's office in Springfield, Virginia.

Lonza Tampa, LLC has applied to the Drug Enforcement Administration to become registered as an importer of controlled substances, specifically focusing on the drug code 7437 (Psilocybin). They plan to use Psilocybin as a bulk active pharmaceutical ingredient for clinical trials, research, and analytical purposes. The DEA is allowing registered bulk manufacturers or applicants to submit electronic comments or objections to this application by March 20, 2025. Requests for a hearing can also be submitted by this date.

The Nuclear Regulatory Commission (NRC) published a monthly notice in accordance with the Atomic Energy Act, outlining proposed amendments to facility operating licenses and combined licenses. These amendments are considered to involve no significant hazards consideration (NSHC) and are effective immediately if determined appropriate by the NRC. Interested parties can submit comments or request hearings by the specified deadlines of April 17, 2025, and May 19, 2025, respectively. Information on obtaining documents and submitting comments is available through various methods, including the NRC's electronic systems.

Aphena Pharma Solutions MD, LLC has applied to the Drug Enforcement Administration (DEA) to be a registered importer of certain controlled substances. These substances will be used internally to manufacture an over-the-counter drug that is approved by the FDA. Interested parties, such as registered bulk manufacturers, can submit electronic comments or objections to this application by April 7, 2025. They can also request a hearing on the application within the same deadline.

The Nuclear Regulatory Commission (NRC) has issued a regular monthly notice under the Atomic Energy Act, allowing amendments to nuclear facility licenses that pose no significant hazards. The period covered for these amendments is from November 7, 2024, to December 5, 2024. The public can comment on these amendments until January 22, 2025, and request hearings until February 21, 2025. For additional information and to make comments, the NRC encourages using electronic submissions through the federal rulemaking website.

Janssen Pharmaceuticals Inc. has filed an application with the Drug Enforcement Administration (DEA) to become an importer of certain controlled substances for analytical purposes. Public comments or objections regarding this application are accepted until March 17, 2025. Hearings can also be requested by this date. Comments should be submitted via the Federal eRulemaking Portal, and requests for hearings must be sent to the DEA at specified addresses.

Fisher Clinical Services, Inc. has applied to the Drug Enforcement Administration (DEA) to register as an importer of certain controlled substances. The company intends to import these substances solely for clinical trials. Other types of uses or commercial sales are not allowed under this registration. Interested parties can submit comments or objections electronically by April 16, 2025, and can also request a hearing on the application by the same date.

The Securities and Exchange Commission (SEC) has released a notice about an application by Guardian Variable Products Trust and Park Avenue Institutional Advisers LLC. They are seeking an exemption from the requirement of the Investment Company Act of 1940 that mandates in-person meetings for approving new or amended sub-advisory agreements. The application was filed on December 13, 2024, and the SEC may hold a hearing if requested by interested parties. Hearing requests must be submitted to the SEC by February 18, 2025.